Connie Markulev1, Patrick D McGorry1, Barnaby Nelson1, Hok Pan Yuen1, Miriam Schaefer1, Alison R Yung2, Andrew Thompson3, Gregor Berger4, Nilufar Mossaheb5, Monika Schlögelhofer5, Stefan Smesny6, Lieuwe de Haan7, Anita Riecher-Rössler8, Merete Nordentoft9, Eric Yu Hai Chen10, Swapna Verma11, Ian Hickie12, G Paul Amminger1. 1. Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Parkville, Victoria, Australia. 2. Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK. 3. Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, UK. 4. Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland. 5. Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. 6. Department of Psychiatry and Psychotherapy, University of Jena, Jena, Germany. 7. Academic Psychiatric Centre, AMC, Amsterdam, The Netherlands. 8. Psychiatric University Clinics, University Psychiatric Outpatient Department, Basel, Switzerland. 9. Department of Psychiatry E, Bispebjerg Hospital, Copenhagen, Denmark. 10. Department of Psychiatry, University of Hong Kong, Hong Kong, Hong Kong. 11. Early Psychosis Intervention, Institute of Mental Health, Singapore, Singapore. 12. Brain & Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia.
Abstract
AIM: Recent research has indicated that preventative intervention is likely to benefit patients 'at-risk' for psychosis, both in terms of symptom reduction and delay or prevention of onset of threshold psychotic disorder. The strong preliminary results for the effectiveness of omega-3 polyunsaturated fatty acids (PUFAs), coupled with the falling transition rate in ultra high-risk (UHR) samples, mean that further study of such benign, potentially neuroprotective interventions is clinically and ethically required. Employing a multicentre approach, enabling a large sample size, this study will provide important information with regard to the use of omega-3 PUFAs in the UHR group. METHODS: This trial is a 6-month, double-blind, randomized placebo-controlled trial of 1.4 g day-1 omega-3 PUFAs in UHR patients aged between 13 and 40 years. The primary hypothesis is that UHR patients receivingomega-3 PUFAs plus cognitive-behavioural case management (CBCM) will be less likely to transition to psychosis over a 6-month period compared to treatment with placebo plus CBCM. Secondary outcomes will examine symptomatic and functional changes, as well as examine if candidate risk factors predict response to omega-3 PUFA treatment in the UHR group. CONCLUSION: This is the protocol of the NeuraproE study. Utilizing a large sample, results from this study will be important in informing indicated prevention strategies for schizophrenia and other psychotic disorders, which may be the strongest avenue for reducing the burden, stigmatization, disability and economic consequences of these disorders.
RCT Entities:
AIM: Recent research has indicated that preventative intervention is likely to benefit patients 'at-risk' for psychosis, both in terms of symptom reduction and delay or prevention of onset of threshold psychotic disorder. The strong preliminary results for the effectiveness of omega-3 polyunsaturated fatty acids (PUFAs), coupled with the falling transition rate in ultra high-risk (UHR) samples, mean that further study of such benign, potentially neuroprotective interventions is clinically and ethically required. Employing a multicentre approach, enabling a large sample size, this study will provide important information with regard to the use of omega-3 PUFAs in the UHR group. METHODS: This trial is a 6-month, double-blind, randomized placebo-controlled trial of 1.4 g day-1 omega-3 PUFAs in UHR patients aged between 13 and 40 years. The primary hypothesis is that UHR patients receiving omega-3 PUFAs plus cognitive-behavioural case management (CBCM) will be less likely to transition to psychosis over a 6-month period compared to treatment with placebo plus CBCM. Secondary outcomes will examine symptomatic and functional changes, as well as examine if candidate risk factors predict response to omega-3 PUFA treatment in the UHR group. CONCLUSION: This is the protocol of the NeuraproE study. Utilizing a large sample, results from this study will be important in informing indicated prevention strategies for schizophrenia and other psychotic disorders, which may be the strongest avenue for reducing the burden, stigmatization, disability and economic consequences of these disorders.
Authors: Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger Journal: Nat Rev Drug Discov Date: 2016-03-04 Impact factor: 84.694
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: S M Cotton; K M Filia; A Ratheesh; K Pennell; S Goldstone; P D McGorry Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2016-01 Impact factor: 4.328
Authors: Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk Journal: Neurosci Biobehav Rev Date: 2016-04-09 Impact factor: 8.989
Authors: Iris E Sommer; Carrie E Bearden; Edwin van Dellen; Elemi J Breetvelt; Sasja N Duijff; Kim Maijer; Therese van Amelsvoort; Lieuwe de Haan; Raquel E Gur; Celso Arango; Covadonga M Díaz-Caneja; Christiaan H Vinkers; Jacob As Vorstman Journal: NPJ Schizophr Date: 2016-03-09